In-depth discussion on neuro therapeutics and strategic priorities for the next 18 months by Actinogen Medical Ltd CEO|Steven Gourlay , CEO, Actinogen Medical Ltd. 00:10:00

Share On Facebook Share On Twitter

The CEO of Actinogen Medical Ltd discusses the company's focus on neuro therapeutics, recent financial highlights, and upcoming strategic priorities for the next 18 months, highlighting their lead compound Xanamem® for treating neurological diseases associated with dysregulated brain cortisol.

Recent Videos